Ones To Watch News
Refine Search
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Biotechnology
US anti-virals major Gilead Sciences’ Kite unit and Arcellx -announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. 10 May 2024
Pharmaceutical
UK respiratory disease specialist Verona Pharma and its wholly-owned subsidiary, Verona Pharma Inc (VPI) have entered into strategic financing agreements securing access to up to $650 million. 10 May 2024
Pharmaceutical
In a bid to retain its leadership position in the ever-expanding obesity sector, Novo Nordisk has inked another research collaboration, adding to a string of M&A and licensing deals over the past couple of years. 9 May 2024
Biotechnology
California-based Attovia Therapeutics has announced the closing of a $105 million oversubscribed Series B financing. 9 May 2024
Biotechnology
California, USA-based Bluejay Therapeutics today announced the successful closure of a $182 million Series C financing round. 9 May 2024
Biotechnology
Companies including Gilead Sciences unit Kite, as well as Boston-based Treos Bio, have outlined data they intend to present at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). 9 May 2024
Pharmaceutical
Israel’s Teva Pharmaceutical Industries and France-based Medincell have announced results from the efficacy portion of the Phase III SOLARIS trial of olanzapine once-monthly long-acting injectable in schizophrenia compared to placebo. 9 May 2024
Biotechnology
Part of a growing trend in the industry, Ligand Pharmaceuticals has inked a royalty financing agreement with immunology company Agenus. 9 May 2024
Biotechnology
Today, the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to delpacibart etedesiran (AOC 1001). 8 May 2024
Pharmaceutical
The US Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting the new drug application (NDA) submitted by Lykos Therapeutics for midomafetamine (MDMA) capsules. 8 May 2024
Biotechnology
Shares of USA-based tumor drug resistance specialist Deciphera Pharmaceuticals soared 73% to $25.34 in morning trading, on the news that it has received a takeover bid. 8 May 2024
Biotechnology
Leading biotech incubator Flagship Pioneering has announced its latest investment, with the launch of a viral proteome start-up, Prologue Medicines. 8 May 2024
Pharmaceutical
Chinese metabolic disease company Sciwind Biosciences has inked a deal with HK inno.N, a South Korean commercial stage drugmaker. 8 May 2024
Series C
American inflammation and immunology (I&I) specialist Zenas BioPharma today announced the closing of an upsized $200 million Series C preferred stock financing. 7 May 2024
Pharmaceutical
A trial flop for Massachusetts, USA-based EyePoint Pharmaceuticals has triggered a sell-off from investors, with the price of a share dropping by around half. 7 May 2024
Pharmaceutical
Swiss drug developer Atopia Therapeutics has appointed Dr Grégoire Chevalier as chief executive (CEO). 7 May 2024
Biotechnology
German biotech BioNTech, which shot into the limelight with the development of the most successful COVID-19 vaccine, Comirnaty, has reported financial results for the three months ended March 31, 2024. 7 May 2024
Biotechnology
Privately-held Italian drugmaker Chiesi Farmaceutici announced a deal with USA-based Gossamer Bio for a global collaboration and license agreement to develop and commercialize the latter’s seralutinib. 7 May 2024
Pharmaceutical
Maryland, USA–based glycobiology specialist GlycoMimetics has seen its share price fall around 80% after the failure of a Phase III trial. 7 May 2024
Series A
Philadelphia, USA-based Latus Bio, a biotech developing novel gene therapy candidates for disorders of the central nervous system (CNS), has announced its launch and an initial close of $54 million in Series A financing. 7 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze